The independent source for health policy research, polling, and news.
401-420 of 1,325 results
At a moment when half of U.S. states stand poised to outlaw or sharply curtail abortion services, the nation’s most popular emergency contraception brand rests in the unlikely stewardship of two private equity firms.
Gov. Gavin Newsom proposed spending $100 million to make insulin affordable to millions of people with diabetes under a new state generic drug label, CalRx. But state officials haven’t said how much the insulin will cost patients or how the state will deal with distribution and other challenges.
KHN gives readers a chance to comment on a recent batch of stories.
After years of failure, the Maryland company aims to attract the vaccine-hesitant with an alternative to mRNA shots. But will it find a market?
The Mashkiki Waakaa’igan Pharmacy in downtown Minneapolis gives Native Americans an economical option for filling prescriptions while being sensitive to tribal traditions and expectations.
KHN Editor-in-Chief Elisabeth Rosenthal joins comedian Adam Conover to discuss his new Netflix series, “The G Word,” which examines the federal government's role in Americans' lives, and how it plays out in the covid era.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Covid cases are again climbing, but you wouldn’t know it from the behavior of public health and elected officials, much less the general public, all of whom seem to want to put the pandemic in the rearview mirror. Meanwhile, the fallout over the leaked Supreme Court draft opinion on abortion continues even as the Senate fails — again — to muster the votes to write abortion rights into law. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Alice Miranda Ollstein of Politico, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.
Many public health workers are unable to see how many doses of Pfizer’s antiviral treatment are shipped to their communities and cannot tell whether vulnerable residents are filling prescriptions as often as their wealthier neighbors.
In California, where overdose deaths are on the rise, physicians say administering anti-addiction medication as a monthly injection holds tremendous potential. So, why aren’t more patients getting it?
The unprecedented early leak of a Supreme Court draft opinion that would overturn the landmark abortion-rights ruling Roe v. Wade has heated the national abortion debate to boiling. Meanwhile, the FDA, after years of consideration, moves to ban menthol flavors in cigarettes and cigars. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Shefali Luthra of the 19th, and Jessie Hellmann of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Paula Andalo, who wrote the latest KHN-NPR “Bill of the Month” episode about a family whose medical debt drove them to seek care south of the border.
Georgia may soon join a growing list of states decriminalizing the use of fentanyl testing strips. Bans of the strips — on the books in about half of states, experts say — stem from laws criminalizing drug paraphernalia adopted decades ago. But the testing devices are now recommended to help prevent overdose deaths.
Even the savviest Medicare drug plan shoppers can get a shock when they fill prescriptions: That great deal on medications is no bargain after prices go up.
In the shadow of Texas’ austere abortion regulations, grassroots organizers employ stealth tactics to help young women get emergency contraception.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
A diabetes diagnosis is not always related to a person’s weight or overall health, especially for those with Type 1 diabetes, who are dependent on insulin treatment for life.
Drug copayment assistance is a form of profitable charity — and, yes, that’s an oxymoron. Amid skyrocketing drug prices, it's understandable that patients desperately need help affording medicine, especially when their health is on the line. But these programs create a mirage that perpetuates our health care system’s reckless spending.
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
KHN gives readers a chance to comment on a recent batch of stories.
© 2026 KFF